Track topics on Twitter Track topics that are important to you
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.
// Starting salary will be commensurate with professional and academic credentials and experience.: Pathobiology: Assistant Professor of Biomolecular Pharmaceutical Pathobiology at Auburn University C...
(University of Tokyo) A Franco-Japanese research group at the University of Tokyo has developed a new 'brute force' technique to test thousands of biochemical reactions at once and quickly home in on ...
&"We will control how the atoms cross the metamaterial, in which direction they will go.&"
Sometimes nature needs a helping hand, but the latest breakthrough from Rice University's Department of Chemical and Biomolecular Engineering might be more accurately described as a whole new arm.
Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.
US biotech firm BIND Therapeutics, a developer of targeted and programmable therapeutics called Accurins,…
BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…
Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BT...
A novel combinatorial biomolecular nanopatterning method is reported, in which multiple biomolecular ligands can be patterned in multiple nanoscale dimensions on a single surface. The applicability of...
We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...
The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
The emergence of oral delivery in cancer therapeutics is expected to result in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treat...
Female urinary incontinence and pelvic organ prolapse are common diseases especially in aged women that frequently cause urogenital infection, voiding difficulty, urinary retention, pelvic...
To evaluate the efficacy of locally delivering plasmid DNAs encoding MIR200c in the promotion of osteogenesis and modulation of the inflammatory response on the basis of different clinical...
The goal of this research study to see whether biofeedback therapy helps treat asthma, and if so, how it works. Biofeedback is a treatment method that can teach people how to control their...
The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.
Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.
A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.
The Society for Biomolecular Sciences' mission is to advance the science of drug discovery and related disciplines by providing a forum for education and information exchange among professionals aroun...
BiOptix offers an affordable and powerful solution for drug discovery scientists that require label-free real-time detection of biomolecular interactions. The unique SPR-enhanced ...
We have published hundreds of BioMolecular Therapeutics, Inc. news stories on BioPortfolio along with dozens of BioMolecular Therapeutics, Inc. Clinical Trials and PubMed Articles about BioMolecular Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics, Inc. Companies in our database. You can also find out about relevant BioMolecular Therapeutics, Inc. Drugs and Medications on this site too.